Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 135; no. 25; pp. 2572 - 2574
Main Authors Virani, Salim S., Akeroyd, Julia M., Nambi, Vijay, Heidenreich, Paul A., Morris, Pamela B., Nasir, Khurram, Michos, Erin D., Bittner, Vera A., Petersen, Laura A., Ballantyne, Christie M.
Format Journal Article
LanguageEnglish
Published United States by the American College of Cardiology Foundation and the American Heart Association, Inc 20.06.2017
Subjects
cardiovascular disease
cholesterol
lipids
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Correspondence-3
content type line 23
ISSN:0009-7322
1524-4539
1524-4539
DOI:10.1161/CIRCULATIONAHA.117.028503